Patent · US Active

Composition comprising recombinant GPlbα receptor protein

US11746140B2 · kind B2 · utility

0Cited by

4References

26Claims

0Family size

Assignee

F. Hoffmann-La Roche AG · CH

Inventors

Elizabeth Booth · Berkeley, US
Virginia Montanini · l'Ametlla del Vallès, ES
John A. Hall · Abdulrahman Khaleefah Street, US
Jody Berry · Easton, US

Key dates

Filing date	Feb 15, 2019
Grant date	Sep 5, 2023
Priority date	—
Expiry date	Feb 15, 2039

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/755
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ibα that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.